Pharmaxis Limited
(ASX:PXS) says the Australian Government has given the green light for its cystic fibrosis drug bronchitol to have simplified access to the Pharmaceutical Benefits Scheme.
The decision removes the need for patients to demonstrate an increase in lung function to secure a PBS reimbursement.
Under the new listing, the criteria will be set by the doctor and patient to allow flexibility in clinical decision-making.
Pharmaxis CEO Gary Phillips says the decision simplifies the process for patients and offers doctors more flexibility in their approach to treating cystic fibrosis.
Pharmaxis booked a net loss of $20.7 million in the first half of fiscal 2013.
